“Microbiome-Competitive Landscape, Technology and Pipeline Analysis, 2016”, report provides comprehensive insights about pipeline drugs across this microbiome based products. This report provides information on the therapeutic development based on the Microbiome dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/209357 .
There are total 73 drugs in pipeline out of which 2 products is in Phase II/III, 8 products in Phase II, 6 product are in Phase I, 1 product are in Phase 0 and 1 Product in IND. Around 34 products are in Pre-clinical, 18 products are in Discovery stage of development and 3 products is in Unknown stage of development. Companies have also gone in collaboration with different partners.
Some Points Of Product Development Activities:
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Companies Planning for Future Development in Microbiome
DelveInsight Consulting Services
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/209357 .
The market of microbiome therapies is progressing rapidly. Various companies are getting on the action, aiming to target microbes to treat various types of diseases. Synlogic is currently developing 6 drugs that address disease by targeting gut microbiome using their synthetic biotics approach. The company is also collaborated with different partners to apply their platform to create innovative synthetic biotics for the treatment of major diseases in disease areas including inflammation, metabolism, oncology and CNS. All products of Synlogic are in Pre-Clinical and Discovery stage. Other companies are also in race for developing the products that target the microbes. Seres therapeutics is also developing the 5 products with their lead program, SER-109 for the prevention of recurrent Clostridium difficile infections, which has granted the Breakthrough therapy by FDA.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Browse Complete Report @ http://www.orbisresearch.com/reports/index/microbiome-competitive-landscape-technology-and-pipeline-analysis-2017 .
Some Points From TOC:
Human Microbiota Ecosystems
Role of Microbiota in Health and Disease
Effects of Probiotics and Prebiotics on gut microbiota
Microbiome Projects under development
Future of Microbiome
Hinderances for Microbiome as therapy
Challenges in studying the microbiome
Unmet needs of Microbiome
Pipeline Products Analysis
Microbiome-Number of Products (N) and Therapy Area
Microbiome Analysis by Therapy Area and Companies
Collaboration with Institutes
Number of Collaboration with Companies Year Wise
For any enquires before buying, connect with us @ email@example.com
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
For more information contact firstname.lastname@example.org